Laura Mediani

Laura Mediani

Auto-generated profile, based on publicly available information

Laura Mediani

Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Modena 41125, Italy

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in Molecular Cell
Verified
Journal Article
Closed access
MGMassimo Ganassi
Massimo Ganassi
DMDaniel Mateju
Daniel Mateju
IBIlaria Bigi
Ilaria Bigi
LMLaura Mediani
Laura Mediani
IPIna Poser
Ina Poser
SCSerena Carra
Serena Carra

25 February 2015 in Cellular and Molecular Life Sciences
Verified
Journal Article
Closed access
PDF file
JBJESSIKA BERTACCHINI
JESSIKA BERTACCHINI
NHNazanin Heidari
Nazanin Heidari
LMLaura Mediani
Laura Mediani
SCSilvano Capitani
Silvano Capitani
MSMohammad Shahjahani
Mohammad Shahjahani
NNajmaldin Saki
Najmaldin Saki

27 March 2017 in Frontiers in Molecular Neuroscience
Verified
Journal Article
Open access
SASimon Alberti
Simon Alberti
DMDaniel Mateju
Daniel Mateju
LMLaura Mediani
Laura Mediani
SCSerena Carra
Serena Carra
Ribonucleoprotein (RNP) granules transport, store, or degrade messenger RNAs, thereby indirectly regulating protein synthesis. Normally, RNP granules are highly dynamic compartments. However, because of aging or severe environmental stress, RNP granules, in particular stress granules (SGs), convert into solid, aggregate-like inclusions. There is increasing evidence that such RNA-protein inclusions are associated with several age-related neurodegenerative diseases, such as amyotrophic lateral sclerosis, frontotemporal dementia and Alzheimer’s disease. Thus, understanding what triggers the conversion of RNP granules into aggregates and identifying the cellular players that control RNP granules will be critical to develop treatments for these diseases. In this review, we discuss recent insight into RNP and stress granule formation. More specifically, we examine the evidence for liquid-liquid phase separation as an organizing principle of RNP granules and the role of aggregation-prone RNA-binding proteins in this process. We further discuss recent findings that liquid-like SGs can sequester misfolded proteins, which promote an aberrant conversion of liquid SGs into solid aggregates. Importantly, very recent studies show that a specific protein quality control process prevents the accumulation of misfolding-prone proteins in SGs and, by doing so, maintains the dynamic state of SGs. This quality control process has been referred to as granulostasis and it relies on the specific action of the HSPB8-BAG3-HSP70 complex. Additional players such as p97/VCP and other molecular chaperones (e.g., HSPB1) participate, directly or indirectly, in granulostasis, and ensure the timely elimination of defective ribosomal products and other misfolded proteins from SGs. Finally, we discuss recent findings that, in the stress recovery phase, SGs are preferentially disassembled with the assistance of chaperones, and we discuss evidence for a back-up system that targets aberrant SGs to the aggresome for autophagy-mediated clearance. Altogether the findings discussed here provide evidence for an intricate network of interactions between RNP granules and various components of the protein quality control machinery. Molecular chaperones in particular are emerging as key players that control the composition and dynamics of RNP granules, which may be important to protect against age-related diseases.

4 July 2019 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
LMLaura Mediani
Laura Mediani
JGJordina Guillén‐Boixet
Jordina Guillén‐Boixet
JVJonathan Vinet
Jonathan Vinet
TFTitus M Franzmann
Titus M Franzmann
IBIlaria Bigi
Ilaria Bigi
SCSerena Carra
Serena Carra
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

21 February 2013 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
JBJESSIKA BERTACCHINI
JESSIKA BERTACCHINI
FBFrancesca Beretti
Francesca Beretti
VCVittoria Cenni
Vittoria Cenni
MGMarianna Guida
Marianna Guida
FGFederica Gibellini
Federica Gibellini
Sandra MarmiroliSandra Marmiroli
Sandra Marmiroli
The serine/threonine kinase Akt/PKB is a major signaling hub integrating metabolic, survival, growth, and cell cycle regulatory signals. The definition of the phospho‐motif cipher driving phosphorylation by Akt led to the identification of hundreds of putative substrates, and it is therefore pivotal to identify those whose phosphorylation by Akt is of consequence to biological processes. The Lmna gene products lamin A/C and the lamin A precursor prelamin A are type V intermediate filament proteins forming a filamentous meshwork, the lamina, underneath the inner nuclear membrane, for nuclear envelope structures organization and interphase chromatin anchoring. In our previous work, we reported that A‐type lamins are phosphorylated by Akt at S301 and S404 in physiological conditions and are therefore bona fide substrates of Akt. We report here that Akt phosphorylation at S404 targets the precursor prelamin A for degradation. We further demonstrate that Akt also regulates Lmna transcription. Our study unveils a previously unknown function of Akt in the control of prelamin A stability and expression. Moreover, given the large number of diseases related to prelamin A, our findings represent a further important step bridging basic A‐type lamin physiology to therapeutic approaches for lamin A‐linked disorders.—Bertacchini, J., Beretti, F., Cenni, V., Guida, M., Gibellini, F., Mediani, L., Marin, O., Maraldi, N. M., de Pol, A., Lattanzi, G., Cocco, L., Marmiroli, S. The protein kinase Akt/PKB regulates both prelamin A degradation and Lmna gene expression. FASEB J. 27, 2145–2155 (2013). www.fasebj.org

4 April 2014 in Leukemia
Verified
Journal Article
Open access
PDF file
JBJESSIKA BERTACCHINI
JESSIKA BERTACCHINI
MGM Guida
M Guida
BAB Accordi
B Accordi
LML Mediani
L Mediani
AMA M Martelli
A M Martelli
Sandra MarmiroliSandra Marmiroli
Sandra Marmiroli
Acute myeloid leukemia (AML) primary cells express high levels of phosphorylated Akt, a master regulator of cellular functions regarded as a promising drug target. By means of reverse phase protein arrays, we examined the response of 80 samples of primary cells from AML patients to selective inhibitors of the phosphatidylinositol 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) axis. We confirm that >60% of the samples analyzed are characterized by high pathway phosphorylation. Unexpectedly, however, we show here that targeting Akt and mTOR with the specific inhibitors Akti 1/2 and Torin1, alone or in combination, result in paradoxical Akt phosphorylation and activation of downstream signaling in 70% of the samples. Indeed, we demonstrate that cropping Akt or mTOR activity can stabilize the Akt/mTOR downstream effectors Forkhead box O and insulin receptor substrate-1, which in turn potentiate signaling through upregulation of the expression/phosphorylation of selected growth factor receptor tyrosine kinases (RTKs). Activation of RTKs in turn reactivates PI3K and downstream signaling, thus overruling the action of the drugs. We finally demonstrate that dual inhibition of Akt and RTKs displays strong synergistic cytotoxic effects in AML cells and downmodulates Akt signaling to a much greater extent than either drug alone, and should therefore be explored in AML clinical setting.